American Century Companies Inc. Sells 258,262 Shares of Enovis Corporation $ENOV

American Century Companies Inc. reduced its holdings in shares of Enovis Corporation (NYSE:ENOV) by 5.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,731,065 shares of the company’s stock after selling 258,262 shares during the quarter. American Century Companies Inc. owned about 8.28% of Enovis worth $143,541,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Farther Finance Advisors LLC lifted its position in shares of Enovis by 42.8% during the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after acquiring an additional 367 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in shares of Enovis during the 2nd quarter valued at $46,000. SJS Investment Consulting Inc. lifted its holdings in Enovis by 30,340.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after purchasing an additional 1,517 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in Enovis by 235.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,703 shares of the company’s stock worth $52,000 after purchasing an additional 1,195 shares during the period. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Adjusted EPS beat — Enovis reported adjusted EPS $0.95 versus consensus ~$0.81, signaling underlying profitability on a non‑GAAP basis. Enovis Q4 2025 Earnings Call Highlights
• Positive Sentiment: Management raised FY2026 adjusted EPS guidance to $3.52–$3.73 (above consensus ~3.35) and expects adjusted EBITDA expansion, providing a clearer path to earnings recovery. Enovis targets $2.31–$2.37B 2026 revenue
• Positive Sentiment: Operational momentum — full‑year 2025 net sales grew ~7% (6% organic) with Reconstructive up ~10% Y/Y; adjusted EBITDA and adjusted EPS for the year improved on a non‑GAAP basis. Enovis Announces Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst activity supportive — BTIG raised its price target to $43 and keeps a buy stance, signaling some sell‑side confidence in the recovery story. BTIG price target raise
• Neutral Sentiment: Guidance mix — revenue guidance of $2.31–$2.37B implies 4–6% organic growth (positive), but the top‑end sits below some street expectations — a watch item for revenue‑sensitive investors. Guidance detail
• Negative Sentiment: Revenue miss and GAAP impairment — Q4 revenue ~$575.8M missed consensus (~$584M) and the company took a $501M non‑cash goodwill impairment (Q4) that produced a large GAAP loss (Q4 net loss from continuing operations ~$519M), raising concerns about past acquisition valuation and near‑term GAAP volatility. Enovis Misses Q4 Sales Expectations
• Negative Sentiment: Significant non‑cash charges dent headline results — investors focused on GAAP losses and goodwill write‑downs may remain cautious despite positive adjusted metrics. Quiver/summary of results and impairment

Enovis Trading Up 0.3%

NYSE ENOV opened at $25.49 on Monday. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. The stock’s 50-day simple moving average is $24.27 and its two-hundred day simple moving average is $28.18. Enovis Corporation has a twelve month low of $21.00 and a twelve month high of $40.69. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -1.23 and a beta of 1.46.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The firm had revenue of $575.76 million during the quarter, compared to analysts’ expectations of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts forecast that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Insider Activity at Enovis

In other news, EVP Daniel A. Pryor sold 999 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.70% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Evercore reiterated an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Wells Fargo & Company boosted their price objective on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Canaccord Genuity Group lowered their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. UBS Group reissued a “buy” rating and issued a $50.00 price target on shares of Enovis in a report on Monday, January 5th. Finally, BTIG Research upped their price target on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Thursday. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.43.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.